Thomas Steyer’s DexCom DXCM Stock Holding History

Thomas Steyer’s Portfolio DXCM Stock Details DXCM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-544,000	Closed	-$50.8M	–	162
2023 Q3	$50.8M	Buy	+544,000	New	+$61.3M	0.24%	58

Other funds holding DXCM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Thomas Steyer's DXCM Position: Q4 2023 in Review

Thomas Steyer sold out of DexCom (DXCM) in Q4 2023, closing a stake of 544,000 shares — an estimated $50.8M sold.

Thomas Steyer first reported a position in DXCM in Q3 2023 and held it in 1 quarter. The position peaked at $50.8M in Q3 2023. 975 funds tracked by Wall St. Rank hold DXCM as of Q4 2023.

Thomas Steyer reported no remaining DexCom position as of Q4 2023 after selling out during the quarter.
Thomas Steyer sold 544,000 DexCom shares in Q4 2023, an estimated $50.8M.
Thomas Steyer first reported a position in DexCom in Q3 2023 and held it in 1 quarter.
Thomas Steyer's DexCom position peaked at $50.8M in Q3 2023.
975 funds tracked by Wall St. Rank held DexCom as of Q4 2023.

Based on Farallon Capital Management's 13F filing for Q4 2023, filed 14 Feb 2024.